Xu Yu, Lu Jieli, Li Mian, Wang Tiange, Wang Kan, Cao Qiuyu, Ding Yi, Xiang Yu, Wang Siyu, Yang Qianqian, Zhao Xuan, Zhang Xiaoyun, Xu Min, Wang Weiqing, Bi Yufang, Ning Guang
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, National Research Center for Translational Medicine, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, National Research Center for Translational Medicine, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lancet Public Health. 2024 Dec;9(12):e1098-e1104. doi: 10.1016/S2468-2667(24)00251-2. Epub 2024 Nov 20.
During the past 40 years, the prevalence of diabetes in China has increased from less than 1·0% in 1980 to 12·4% in 2018, an increase in line with the rapid growth of the nation's economy. To address such a burden, the Healthy China 2030 initiative and subsequent Action Plan, including a diabetes prevention and control campaign, were launched. A shift from a disease-centred approach to a health-centred approach and from treatment to prevention is the core of the Action Plan and diabetes management in China. In this Review, we discuss the challenges of diabetes prevention in China, including unhealthy lifestyle, increasing young-onset type 2 diabetes, and substantial diabetes care disparities. To address such challenges, countermeasures across different stages of diabetes prevention and targeted at different populations, are needed. Such countermeasures include primordial prevention of risk factors in the general population, primary prevention of diabetes onset in high-risk populations, and secondary prevention of cardiovascular complications for individuals with diabetes. We reflect on China's current progress, strategies, and achievements.
在过去40年里，中国糖尿病患病率从1980年的不到1.0%升至2018年的12.4%，这一增长与国家经济的快速发展同步。为应对这一负担，中国启动了“健康中国2030”规划及后续行动计划，其中包括糖尿病防控行动。从以疾病为中心的方法转向以健康为中心的方法，从治疗转向预防，是该行动计划和中国糖尿病管理的核心。在本综述中，我们讨论了中国糖尿病预防面临的挑战，包括不健康的生活方式、青年发病2型糖尿病的增加以及糖尿病护理方面的巨大差距。为应对这些挑战，需要针对不同人群、在糖尿病预防的不同阶段采取对策。这些对策包括在一般人群中对危险因素进行原级预防，在高危人群中对糖尿病发病进行一级预防，以及对糖尿病患者进行心血管并发症的二级预防。我们还反思了中国目前的进展、策略和成就。
